BioWa Announces Second Japanese License of POTELLIGENT(R) Technology to Otsuka Pharmaceutical
PRINCETON, N.J., Oct. 5 /PRNewswire/ — BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa’s POTELLIGENTÃ‚® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC). BioWa’s first Japanese pharmaceutical POTELLIGENTÃ‚® License was initiated in May, 2007 with Takeda Pharmaceutical Company Limited.
“We are delighted about our partnership with Otsuka, a global healthcare company with a strong tradition in molecular discovery,” commented Dr. Masamichi Koike, BioWa’s President and CEO. “We are pleased to be in a position to augment Otsuka’s impressive pipeline.”
Under the terms of the license agreement, BioWa grants Otsuka non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through POTELLIGENTÃ‚® Technology for an undisclosed number of targets. In return, BioWa will receive an upfront payment, development milestone payments and royalties on products. Other details of the agreement are not disclosed.
About POTELLIGENTÃ‚® Technology
POTELLIGENTÃ‚® Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENTÃ‚® Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENTÃ‚® Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENTÃ‚® antibodies are being investigated in human clinical trials.
About BioWa, Inc.
BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan’s leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of AccretaMab(TM) platform. AccretaMab(TM) platform consists of POTELLIGENTÃ‚® and COMPLEGENT(TM) Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENTÃ‚® and COMPLEGENT(TM) Technologies to partners under a license to maximize the value of these technologies. Together with Kyowa Hakko Kirin, BioWa is committed to promote ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. For more information about BioWa, visit its web site at www.biowa.com.
POTELLIGENTÃ‚®, COMPLEGENT(TM), and AccretaMab(TM) are the trademarks of Kyowa Hakko Kirin Co., Ltd. All rights are reserved.
SOURCE BioWa, Inc.